Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
ACTIVE NOT RECRUITING
NCT04123379
PHASE2

Neoadjuvant Nivolumab with CCR2/5-inhibitor or Anti-IL-8) for Non-small Cell Lung Cancer (NSCLC) or Hepatocellular Carcinoma (HCC)

Sponsor: Icahn School of Medicine at Mount Sinai

View on ClinicalTrials.gov

Summary

The purpose of this research study is to study the effect of giving nivolumab with CCR2/5-inhibitor or anti-IL-8 before surgery, and after surgery, with the goal of determining if this medicine results in: 1. A significant immune response against their tumor (which the study team will see in the tumor that is taken out at the time of surgery) 2. Improvement in long term survival rates

Official title: Tisch Cancer Institute - BMS Study # CA027-005: Neoadjuvant Nivolumab + BMS-813160 (CCR2/5-inhibitor) or BMS-986253 (anti-IL-8) for NSCLC or HCC

Key Details

Gender

All

Age Range

18 Years - 99 Years

Study Type

INTERVENTIONAL

Enrollment

48

Start Date

2020-03-05

Completion Date

2025-12-31

Last Updated

2025-01-17

Healthy Volunteers

No

Interventions

DRUG

Nivolumab

q4w, dosed twice before surgery and three times following recovery from surgery by injection

DRUG

BMS-813160

300mg oral twice a day for 28 days

DRUG

BMS-986253

2400mg once by injection

Locations (1)

Icahn School of Medicine at Mount Sinai

New York, New York, United States